According to the Communication and Information Center in the Vice Presidency of Science, Technology and Knowledge Economy, this morning in the presence of Ruhollah Dehghani, Vice President of Science, Technology and Knowledge Economy, Mustafa Ghanei, Secretary of the Health Knowledge-Based Economy Development Headquarters, and health officials, the country's largest insulin production line was put into operation on an industrial scale.

Vice President of Science, Technology and Knowledge-based Economy in the ceremony of operating the production line of insulin substance from cells said: With the help of a knowledge-based company that is multinational and young domestic specialists have a significant contribution in it, the production of insulin for the first time in the country has been investigated. This achievement is more than a technological achievement, it is a national achievement and brings more authority to the country because in the past years, we had serious problems due to lack of insulin in the country.

Dehghani stated that in addition to meeting the domestic needs, this huge factory will also provide the possibility of exports, adding: This ability will place Iran among the countries capable of producing this strategic material and will bring many achievements to the country.

Referring to the country's capacities in the field of pharmaceuticals and the existence of opportunities for foreign investments in the field of health, he said: Iran is one of the most powerful countries with technology in the field of pharmaceuticals in the world, and there are very good opportunities to be present in the international arena, as well as the presence of international investors in this country. There is an arena; In this regard, the government also supports investors to develop their activities in Iran.

This production line has been formed for the first time in the industrial infrastructure created by the knowledge-based company Vitan Pharmed and will realize the annual production capacity of 700 kg of insulin from the cellular stage in the country's largest pharmaceutical production infrastructure; In case of obtaining clinical approvals, industrial production and supply of this product to the health market, it will lead to foreign exchange savings of more than 100 million euros for the country.

Although before this insulin was imported from India and European countries and Iran only did the process of packaging and filling pharmaceutical vials, but today, with the ability and efforts of the technologists of this knowledge-based company, Iran owns the technology of insulin production from the first stage, the cellular part, to Its processing and production. A step forward that places Iran among the few countries with the technological ability to produce insulin.

Iran being among the countries that have the technology to produce insulin from the cell stage, provides for the needs of the country's health sector, so that if sanctions policies are adopted and restrictions are imposed on the entry of insulin into the country, more than one million patients who use this medicinal substance can receive insulin.

This achievement, in addition to establishing pharmaceutical authority and security, will lay the groundwork for creating employment for dozens of specialized human resources, as well as preventing the outflow of foreign currency through self-sufficiency in the supply of insulin as a relatively expensive and strategic drug.